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The main steps in the viral entry process are (1) attachment of the viral gp120 to the CD4 T cell receptor, (2) binding of 
the gp120 to CCR5 or CXCR4 co-receptors and (3) fusion of the viral and cellular membranes1.  
Currently, two drugs that seem to inhibit efficiently the HIV entry process, namely Maraviroc and Enfurtivide, have 
been approved by FDA (American Food and Drug Administration) for therapeutic use. Nevertheless, the outbreak of 
drug resistance during the therapeutic approach requires continuous and unceasing design of new antivirals2. 
As a part of a research program focused on the development of new entry inhibitors cytosine-based system (as depicted  
in figure 1), preliminary conformational analysis have showed  the core moiety to provide adequate facial orientation in 
the gp120-CD4 receptor complex,  particularly when functional groups suitable for insertion of additional structural 
elements are present in their molecules. 
To improve the results previously obtained and considered the promising biological activity in vitro, tested at Xpress 
Bio-laboratories (Maryland, USA), we decided to generate new potential inhibitory scaffolds by structural 
modifications at the N-1 and N-4 positions. We report herein design and synthesis of all these molecules that  are, 
actually, under biological evaluation. 
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